MSC2364447C Phase 1b in Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 4, 2016

Study Completion Date

October 4, 2016

Conditions
Lupus Erythematosus, Systemic
Interventions
DRUG

MSC2364447C

Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.

DRUG

MSC2364447C

Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.

DRUG

Placebo

Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.

Trial Locations (13)

1336

Research site, Sofia

1431

Research site, Sofia

1612

Research site, Sofia

32713

Research site, DeBary

32806

Research site, Orlando

33765

Research site, Clearwater

36207

Research site, Anniston

48439

Research site, Grand Blanc

63117

Research site, St Louis

78745

Research site, Austin

90048

Research site, Los Angeles

90712

Research site, Lakewood

92020-4124

Research site, El Cajon

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

EMD Serono Research & Development Institute, Inc.

INDUSTRY

NCT02537028 - MSC2364447C Phase 1b in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter